Some providers take a one-size-fits all approach to injectable (parenteral) pharmaceutical development, limiting innovation and settling for standard solutions. We thrive on finding the non-conventional answers that keep you ahead of the competition.
Common Injection Drug Delivery Routes
- Subcutaneous (under the skin)
- Intramuscular (in a muscle)
- Intravenous (in a vein)
- Intradermal (between skin layers)
Injectable Drug Development Considerations
- Pharmacokinetic Modification: Excellent route for long-acting, slow-release formulations designed to keep a drug in the therapeutic window and out of the adverse range.
- Complex Vehicles: Specialized, poorly water-soluble vehicles, such as lipids, can be used for IM drug delivery.
- Volumes restrictions: low injectable volumes (generally <3.5 mL for adults) requires creative solutions to reach the often-necessary high drug concentrations.
- Viscosity: Aforementioned requirement of high drug concentrations can result in viscous formulations (>10 cP) that cause patient discomfort—careful excipient selection and formulation technique can help prevent this.
- Dilutable Formulation: Drug formulation must have sufficient solution stability—especially upon dilution into an IV bag—to allow for longer infusion times (>1 hr) and for the possibility of a multi-use vial.
- Storage Stability: Drugs with stability concerns (e.g., moisture sensitivity) are often lyophilized—a widely accepted dosage form for IV administration
- Syringeability & Injectability: drug formulation must be constructed to allow for trouble-free drawing and administration, especially for smaller gauges (e.g., 30G or less)
- Viscosity: Low viscosity, low foaming formulations must be designed
Contact us to learn about our creative injectable (parenteral) drug formulation solutions, including the use of Apisolex™, a safe, GMP-validated polymer technology
PARTNER WITH CALLAN PHARMA
Callan Pharma provides its partners rapid, comprehensive and cost-effective solutions for their difficult formulation development projects.